
  
    
      
        Background_NNP
        Most_JJS eukaryotic_JJ mRNAs_NNS are_VBP translated_VBN through_IN a_DT
        cap-dependent_JJ mechanism_NN of_IN initiation_NN ._. In_IN this_DT process_NN ,_,
        eIF_NN 4_CD E_NNP ,_, which_WDT functions_NNS by_IN binding_VBG the_DT 7_CD -_: methylguanosine_NN
        cap_NN ,_, is_VBZ the_DT rate-limiting_JJ factor_NN due_JJ to_TO its_PRP$ low_JJ abundance_NN [_NN
        1_CD 2_CD ]_NN ._. In_IN normal_JJ cells_NNS ,_, elevated_VBD eIF_NN 4_CD E_NNP activity_NN is_VBZ
        associated_VBN with_IN proliferation_NN and_CC is_VBZ regulated_VBN by_IN multiple_JJ
        mechanisms_NNS ._. eIF_NN 4_CD E_NNP gene_NN transcription_NN is_VBZ enhanced_VBN in_IN
        response_NN to_TO mitogenic_JJ stimulation_NN and_CC may_MD be_VB mediated_JJ by_IN
        c-myc_JJ [_NN 3_CD ]_NN ._. Phosphorylation_NNP of_IN eIF_NN 4_CD E_NNP by_IN the_DT protein_NN
        kinase_NN Mnk_NNP 1_CD increases_VBZ its_PRP$ affinity_NN for_IN the_DT cap_NN ,_, and_CC thus_RB
        increases_VBZ cap-dependent_JJ initiation_NN of_IN translation_NN [_NN 4_CD 5_CD 6_CD ]_NN
        ._. An_DT inhibitor_NN of_IN eIF_NN 4_CD E_NNP ,_, 4_CD E_NNP binding_JJ protein_NN (_( 4_CD EBP_NNP )_) ,_, is_VBZ also_RB
        regulated_VBN by_IN phosphorylation_NN ._. Phosphorylation_NNP of_IN 4_CD EBP_NNP
        disrupts_NNS its_PRP$ ability_NN to_TO bind_NN eIF_NN 4_CD E_NNP ,_, freeing_VBG eIF_NN 4_CD E_NNP to_TO bind_NN
        eIF_NN 4_CD G_NNP ,_, which_WDT functions_NNS to_TO recruit_VB additional_JJ components_NNS of_IN
        the_DT initiation_NN complex_JJ [_NN 7_CD 8_CD ]_NN ._. The_DT net_JJ result_NN is_VBZ that_DT
        phosphorylation_NN of_IN 4_CD EBP_NNP enhances_VBZ cap-dependent_JJ translation_NN
        initiation_NN ._. 4_LS EBP_NNP phosphorylation_NN is_VBZ thought_VBN to_TO be_VB mediated_JJ
        by_IN mammalian_JJ target_NN of_IN rapamycin_NN (_( mTOR_NN )_) in_IN mitogen_NN
        stimulated_VBN cells_NNS [_NN 9_CD 10_CD 11_CD ]_NN ._.
        Numerous_JJ studies_NNS have_VBP implicated_VBN eIF_NN 4_CD E_NNP in_IN formation_NN and_CC
        progression_NN of_IN tumors_NNS ._. Overexpression_NNP of_IN eIF_NN 4_CD E_NNP leads_VBZ to_TO
        deregulated_VBN growth_NN and_CC malignant_JJ transformation_NN of_IN a_DT
        variety_NN of_IN cultured_JJ cell_NN lines_NNS [_NN 12_CD 13_CD 14_CD ]_NN ._. Moreover_RB ,_,
        elevated_VBD levels_NNS of_IN eIF_NN 4_CD E_NNP are_VBP commonly_RB found_VBN in_IN solid_JJ
        tumors_NNS ,_, especially_RB in_IN breast_NN ,_, colon_NN ,_, and_CC head_NN and_CC neck_NN
        tumors_NNS [_NN 15_CD ]_NN ._. Clinical_NNP studies_NNS indicate_VBP that_DT eIF_NN 4_CD E_NNP gene_NN
        amplification_NN and_CC protein_NN overexpression_NN is_VBZ associated_VBN with_IN
        malignant_JJ progression_NN in_IN these_DT tumors_NNS [_NN 16_CD ]_NN ._. High_NNP eIF_NN 4_CD E_NNP
        levels_NNS are_VBP also_RB associated_VBN with_IN a_DT higher_JJR rate_NN of_IN cancer_NN
        recurrence_NN and_CC cancer-related_JJ death_NN [_NN 17_CD ]_NN ._. In_IN contrast_NN to_TO
        eIF_NN 4_CD E_NNP ,_, overexpression_NN of_IN 4_CD EBP_NNP inhibits_NNS cell_NN proliferation_NN [_NN
        18_CD ]_NN and_CC 4_CD EBP-_NNP 1_CD expression_NN levels_NNS are_VBP inversely_RB correlated_JJ
        with_IN the_DT progression_NN of_IN certain_JJ types_NNS of_IN tumors_NNS [_NN 19_CD ]_NN
        ._.
        The_DT findings_NNS summarized_VBD above_IN indicate_VBP that_WDT elevated_JJ
        eIF_NN 4_CD E_NNP activity_NN plays_VBZ a_DT fundamental_JJ role_NN in_IN cancer_NN formation_NN
        and_CC progression_NN and_CC suggest_VBP the_DT possibility_NN that_DT eIF_NN 4_CD E_NNP
        could_MD be_VB exploited_VBN as_IN a_DT therapeutic_JJ target_NN ._. This_DT is_VBZ
        supported_VBN by_IN several_JJ recent_JJ investigations_NNS ._. Inhibiting_NNP the_DT
        expression_NN of_IN eIF_NN 4_CD E_NNP by_IN expressing_VBG antisense_NN RNA_NNP reverses_VBZ
        ras-mediated_JJ transformation_NN of_IN cultured_JJ cells_NNS as_IN indicated_VBN
        by_IN decreased_VBD efficiency_NN of_IN growth_NN in_IN soft_JJ agar_NN and_CC tumor_NN
        formation_NN in_IN nude_JJ mice_NNS [_NN 20_CD ]_NN ._. Similarly_RB ,_,
        antisense-mediated_JJ reduction_NN of_IN eIF_NN 4_CD E_NNP in_IN breast_NN cancer_NN
        cells_NNS inhibits_NNS both_DT their_PRP$ tumorigenic_JJ and_CC angiogenic_JJ
        properties_NNS [_NN 21_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_, overexpression_NN of_IN
        4_CD EBP_NNP reverses_VBZ transformation_NN mediated_JJ by_IN v-src_JJ [_NN 18_CD ]_NN ._.
        Rapamycin_NNP and_CC its_PRP$ analogs_NNS are_VBP potent_JJ inhibitors_NNS of_IN mTOR_NN
        and_CC lead_VB to_TO cell_NN cycle_NN arrest_NN ._. Thus_RB there_EX is_VBZ interest_NN in_IN
        using_VBG this_DT class_NN of_IN inhibitors_NNS for_IN chemotherapeutic_JJ
        treatment_NN of_IN cancer_NN and_CC several_JJ phase_NN I_PRP trials_NNS have_VBP been_VBN
        carried_VBN out_IN [_NN 22_CD ]_NN ._. Treatment_NNP of_IN mammalian_JJ cells_NNS with_IN
        rapamycin_NN leads_VBZ to_TO dephosphorylation_NN and_CC activation_NN of_IN
        4_CD EBP_NNP ,_, which_WDT in_IN turn_NN binds_NNS to_TO and_CC inhibits_NNS eIF_NN 4_CD E_NNP ._. However_RB ,_,
        several_JJ other_JJ targets_NNS downstream_JJ of_IN mTOR_NN are_VBP also_RB affected_VBN
        by_IN rapamycin_NN ._. These_DT include_VBP effects_NNS on_IN other_JJ translational_NN
        control_NN proteins_NNS including_VBG p_NN 70_CD S_NNP 6_CD kinase_NN (_( p_NN 70_CD S_NNP 6_CD K_NNP )_) ,_, eIF_NN 4_CD G_NNP ,_,
        eIF_NN 4_CD B_NNP ,_, and_CC eEF_NN 2_CD (_( reviewed_VBN in_IN [_NN 23_CD ]_NN )_) ._. At_IN present_VB neither_DT
        the_DT targets_NNS that_WDT are_VBP essential_JJ for_IN inhibition_NN of_IN cell_NN
        proliferation_NN by_IN rapamycin_NN nor_CC the_DT mechanism_NN by_IN which_WDT these_DT
        targets_NNS mediate_VB cell_NN cycle_NN arrest_NN are_VBP completely_RB
        understood_VBN ._.
        In_IN the_DT present_JJ study_NN an_DT MCF_NNP 7_CD breast_NN cancer_NN cell_NN line_NN was_VBD
        developed_VBN which_WDT can_MD be_VB induced_VBN to_TO express_VB a_DT mutant_JJ form_NN of_IN
        4_CD EBP-_NNP 1_CD in_IN which_WDT five_CD amino_JJ acids_NNS that_WDT are_VBP targets_NNS for_IN
        phosphorylation_NN have_VBP been_VBN changed_VBN to_TO alanines_NNS [_NN 24_CD ]_NN ._.
        Since_IN the_DT protein_NN cannot_NN be_VB inactivated_JJ by_IN phosphorylation_NN
        it_PRP constitutively_RB binds_NNS to_TO and_CC inhibits_NNS eIF_NN 4_CD E_NNP ._. Thus_RB
        expression_NN of_IN the_DT mutant_JJ mimics_VBZ the_DT effects_NNS of_IN rapamycin_NN on_IN
        4_CD EBP_NNP but_CC does_VBZ not_RB affect_VB the_DT other_JJ targets_NNS of_IN mTOR_NN ._.
        Induction_NNP of_IN the_DT constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD leads_VBZ to_TO cell_NN
        cycle_NN arrest_NN which_WDT correlates_NNS with_IN loss_NN of_IN cyclin_NN D_NNP 1_CD
        expression_NN and_CC increased_VBN levels_NNS of_IN the_DT cyclin_NN dependent_JJ
        kinase_NN inhibitor_NN p_NN 27_CD Kip_NNP 1_CD ._. The_DT increase_NN in_IN p_NN 27_CD Kip_NNP 1_CD is_VBZ
        mediated_JJ ,_, at_IN least_JJS in_IN part_NN ,_, by_IN enhanced_JJ synthesis_NN of_IN the_DT
        protein_NN and_CC corresponds_NNS to_TO activation_NN of_IN the_DT p_NN 27_CD Kip_NNP 1_CD mRNA_NN
        5_CD '_POS -_: untranslated_JJ region_NN (_( UTR_NNP )_) and_CC its_PRP$ ability_NN to_TO mediate_VB
        cap-independent_JJ initiation_NN of_IN translation_NN ._.
      
      
        Results_NNS
        
          Expression_NNP of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD inhibits_NNS
          the_DT proliferation_NN of_IN MCF_NNP 7_CD cells_NNS
          To_TO test_VB the_DT effect_NN of_IN 4_CD EBP-_NNP 1_CD on_IN the_DT proliferation_NN of_IN
          human_JJ breast_NN cancer_NN cells_NNS ,_, an_DT expression_NN vector_NN encoding_VBG
          the_DT constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD mutant_JJ (_( 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT )_) was_VBD
          stably_RB transfected_JJ into_IN MCF_NNP 7_CD cells_NNS ._. The_DT 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cDNA_NN
          was_VBD placed_VBN under_IN the_DT control_NN of_IN a_DT promoter_NN that_WDT is_VBZ
          responsive_JJ to_TO the_DT insect_NN hormone_NN ponasterone_NN A_DT (_( pon_NN A_DT )_) ,_,
          an_DT ecdysone_NN analog_NN ._. In_IN the_DT absence_NN of_IN pon_NN A_DT an_DT ecdysone_NN
          receptor_NN /_NN VP_NNP 16_CD fusion_NN protein_NN actively_RB represses_NNS the_DT
          promoter_NN leading_VBG to_TO very_RB low_JJ basal_NN levels_NNS of_IN expression_NN ._.
          In_IN the_DT presence_NN of_IN pon_NN A_DT the_DT ecdysone_NN receptor_NN recruits_VBZ
          coactivators_NNS that_WDT lead_VBP to_TO elevated_VBD expression_NN ._. The_DT stably_RB
          transfected_JJ MCF_NNP 7_CD line_NN (_( MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT )_) was_VBD treated_VBN with_IN
          pon_NN A_DT and_CC at_IN various_JJ times_NNS cells_NNS were_VBD harvested_VBN for_IN
          analysis_NN of_IN 4_CD EBP-_NNP 1_CD expression_NN by_IN Western_NNP blotting_VBG (_( Fig_NNP ._.
          1_LS A_DT )_) ._. Several_JJ forms_NNS of_IN 4_CD EBP-_NNP 1_CD are_VBP present_JJ in_IN the_DT stably_RB
          transfected_JJ MCF_NNP 7_CD cells_NNS ._. The_DT slower_JJR migrating_VBG bands_NNS
          represent_VBP endogenous_JJ 4_CD EBP-_NNP 1_CD that_WDT is_VBZ phosphorylated_JJ at_IN
          various_JJ sites_NNS ._. The_DT fastest_JJS migrating_VBG band_NN corresponds_NNS to_TO
          hypophosphorylated_JJ 4_CD EBP-_NNP 1_CD ._. Treatment_NNP with_IN pon_NN A_DT leads_VBZ to_TO
          a_DT rapid_JJ increase_NN in_IN the_DT intensity_NN of_IN the_DT fastest_JJS
          migrating_VBG band_NN ,_, which_WDT corresponds_NNS to_TO the_DT 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT
          mutated_VBN form_NN of_IN the_DT protein_NN which_WDT cannot_NN be_VB
          phosphorylated_JJ ._. In_IN cells_NNS treated_VBN with_IN pon_NN A_DT ,_, the_DT fastest_JJS
          migrating_VBG form_NN of_IN 4_CD EBP-_NNP 1_CD is_VBZ the_DT predominant_NN band_NN at_IN all_DT
          time_NN points_NNS ._. Expression_NNP of_IN this_DT form_NN of_IN 4_CD EBP-_NNP 1_CD continues_VBZ
          to_TO increase_VB for_IN at_IN least_JJS five_CD days_NNS after_IN treatment_NN with_IN
          pon_NN A_DT ._. In_IN the_DT control_NN cells_NNS ,_, which_WDT were_VBD not_RB treated_VBN with_IN
          pon_NN A_DT ,_, phosphorylated_JJ ,_, inactive_JJ 4_CD EBP-_NNP 1_CD is_VBZ the_DT predominant_NN
          form_NN of_IN the_DT protein_NN (_( Fig_NNP ._. 1_LS A_DT )_) ._. Treatment_NNP of_IN untransfected_JJ
          MCF_NNP 7_CD cells_NNS with_IN pon_NN A_DT had_VBD no_DT effect_NN on_IN expression_NN or_CC
          phosphorylation_NN status_NN of_IN 4_CD EBP-_NNP 1_CD (_( data_NNS not_RB shown_VBN )_) ._. The_DT
          expressed_VBD 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT protein_NN is_VBZ active_JJ as_IN determined_VBN by_IN a_DT
          large_JJ increase_NN in_IN the_DT amount_NN of_IN 4_CD EBP-_NNP 1_CD bound_VBN to_TO eIF_NN 4_CD E_NNP in_IN
          pon_NN A_DT treated_VBN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) ._.
          Expression_NNP of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD ,_, through_IN
          inhibition_NN of_IN eIF_NN 4_CD E_NNP activity_NN ,_, would_MD be_VB expected_VBN to_TO slow_VB
          the_DT rate_NN of_IN proliferation_NN of_IN MCF_NNP 7_CD cells_NNS ._. To_TO test_VB this_DT ,_,
          the_DT growth_NN of_IN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT breast_NN cancer_NN cells_NNS was_VBD
          determined_VBN by_IN counting_VBG cell_NN number_NN in_IN cultures_NNS treated_VBN
          with_IN or_CC without_IN pon_NN A_DT (_( Fig_NNP ._. 1_LS C_NNP )_) ._. In_IN the_DT absence_NN of_IN pon_NN A_DT ,_,
          the_DT cells_NNS continued_VBD to_TO proliferate_VBP for_IN at_IN least_JJS five_CD
          days_NNS ._. However_RB ,_, induction_NN of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT by_IN the_DT addition_NN of_IN
          pon_NN A_DT almost_RB completely_RB blocked_VBN cell_NN proliferation_NN ._. There_EX
          was_VBD no_DT indication_NN of_IN cell_NN death_NN in_IN the_DT pon_NN A_DT treated_VBN
          cultures_NNS and_CC pon_NN A_DT had_VBD no_DT effect_NN on_IN the_DT untransfected_JJ
          parental_JJ MCF_NNP 7_CD cell_NN line_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. These_DT results_NNS indicate_VBP
          that_DT expression_NN of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD leads_VBZ to_TO
          cell_NN cycle_NN arrest_NN of_IN MCF_NNP 7_CD cells_NNS ._.
        
        
          Expression_NNP of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT results_NNS in_IN enhanced_JJ p_NN 27_CD
          Kip_NNP 1_CD expression_NN and_CC downregulation_NN of_IN cyclin_NN D_NNP 1_CD
          Elevated_NNP levels_NNS of_IN eIF_NN 4_CD E_NNP are_VBP associated_VBN with_IN
          tumorigenic_JJ transformation_NN and_CC enhanced_JJ expression_NN of_IN
          specific_JJ cell_NN cycle_NN regulatory_JJ proteins_NNS such_JJ as_IN cyclin_NN
          D_NNP 1_CD ._. Expression_NNP of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD should_MD
          lead_VB to_TO a_DT global_JJ decrease_NN in_IN cap-dependent_JJ translation_NN
          which_WDT could_MD lead_VB to_TO cell_NN cycle_NN arrest_NN ._. However_RB ,_, it_PRP is_VBZ
          also_RB possible_JJ that_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD inhibits_NNS
          proliferation_NN through_IN specific_JJ effects_NNS on_IN cell_NN cycle_NN
          regulatory_JJ proteins_NNS ._. Therefore_RB ,_, a_DT number_NN of_IN G_NNP 1_CD cell_NN cycle_NN
          regulatory_JJ molecules_NNS were_VBD examined_VBN in_IN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT
          cells_NNS that_WDT had_VBD been_VBN treated_VBN with_IN or_CC without_IN pon_NN A_DT ._.
          Addition_NNP of_IN pon_NN A_DT altered_VBD the_DT levels_NNS of_IN two_CD critical_JJ G_NNP 1_CD
          regulatory_JJ proteins_NNS ._. There_EX was_VBD a_DT significant_JJ increase_NN in_IN
          the_DT level_NN of_IN p_NN 27_CD Kip_NNP 1_CD observed_VBD at_IN every_DT time_NN point_NN up_IN to_TO
          three_CD days_NNS after_IN addition_NN of_IN pon_NN A_DT (_( Fig_NNP ._. 2_LS Aand_NNP 2_CD B_NNP )_) ._. At_IN
          the_DT same_JJ time_NN there_EX was_VBD a_DT substantial_JJ decrease_NN in_IN the_DT
          level_NN of_IN cyclin_NN D_NNP 1_CD ._. No_DT difference_NN was_VBD observed_VBN in_IN the_DT
          protein_NN levels_NNS of_IN CDK_NNP 4_CD or_CC CDK_NNP 2_CD between_IN pon_NN A_DT treated_VBN and_CC
          untreated_JJ cells_NNS ._. Treatment_NNP of_IN MCF_NNP 7_CD -_: pERV_NN 3_CD cells_NNS ,_, which_WDT
          express_VBP the_DT ecdysone_NN receptor_NN /_NN VP_NNP 16_CD fusion_NN protein_NN but_CC not_RB
          the_DT inducible_JJ constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD (_( see_VB Methods_NNP )_) ,_,
          with_IN pon_NN A_DT had_VBD no_DT effect_NN on_IN the_DT expression_NN of_IN any_DT of_IN
          these_DT proteins_NNS (_( Fig_NNP ._. 2_LS B_NNP )_) ._.
        
        
          Constitutively_NNP active_JJ 4_CD EBP-_NNP 1_CD does_VBZ not_RB alter_VB p_NN 27_CD
          Kip_NNP 1_CD and_CC cyclin_NN D_NNP 1_CD turnover_NN rates_NNS
          The_DT results_NNS above_IN suggest_VBP that_DT cell_NN cycle_NN arrest_NN of_IN
          MCF_NNP 7_CD cells_NNS in_IN response_NN to_TO 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT expression_NN involves_VBZ
          specific_JJ effects_NNS on_IN expression_NN of_IN cyclin_NN D_NNP 1_CD and_CC p_NN 27_CD Kip_NNP 1_CD ._.
          The_DT most_RBS plausible_JJ explanation_NN is_VBZ that_IN the_DT observed_VBN
          changes_NNS are_VBP mediated_JJ by_IN altered_VBN rates_NNS of_IN translation_NN ._.
          However_RB ,_, others_NNS have_VBP shown_VBN that_DT eIF_NN 4_CD E_NNP overexpression_NN
          enhances_VBZ cyclin_NN D_NNP 1_CD mRNA_NN transport_NN from_IN the_DT nucleus_NN to_TO the_DT
          cytosol_NN [_NN 25_CD ]_NN and_CC it_PRP is_VBZ possible_JJ that_IN 4_CD EBP-_NNP 1_CD affects_VBZ
          this_DT process_NN ._. Also_RB ,_, p_NN 27_CD Kip_NNP 1_CD expression_NN is_VBZ actually_RB
          enhanced_VBN while_IN 4_CD EBP-_NNP 1_CD would_MD be_VB expected_VBN to_TO inhibit_VB
          translation_NN rates_NNS ._. Therefore_RB it_PRP was_VBD of_IN interest_NN to_TO
          examine_VB the_DT mechanism_NN by_IN which_WDT 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT expression_NN
          modulates_NNS p_NN 27_CD Kip_NNP 1_CD and_CC cyclin_NN D_NNP 1_CD levels_NNS ._.
          First_LS ,_, to_TO determine_VB if_IN 4_CD EBP-_NNP 1_CD led_VBN to_TO a_DT change_NN in_IN
          degradation_NN of_IN either_DT p_NN 27_CD Kip_NNP 1_CD or_CC cyclin_NN D_NNP 1_CD ,_, turnover_NN
          rates_NNS were_VBD estimated_VBN in_IN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS that_WDT had_VBD
          been_VBN treated_VBN with_IN or_CC without_IN pon_NN A_DT for_IN 24_CD hours_NNS ._.
          Cycloheximide_NNP was_VBD added_VBN for_IN various_JJ times_NNS and_CC p_NN 27_CD Kip_NNP 1_CD and_CC
          cyclin_NN D_NNP 1_CD levels_NNS were_VBD estimated_VBN by_IN western_JJ blotting_VBG (_( Fig_NNP ._.
          3_LS )_) ._. Neither_DT the_DT rate_NN of_IN p_NN 27_CD Kip_NNP 1_CD turnover_NN nor_CC that_IN of_IN
          cyclin_NN D_NNP 1_CD was_VBD significantly_RB altered_VBN by_IN pon_NN A-_NNP induced_VBD
          expression_NN of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ._. Thus_RB ,_, modulation_NN of_IN p_NN 27_CD Kip_NNP 1_CD and_CC
          cyclin_NN D_NNP 1_CD levels_NNS in_IN response_NN to_TO expression_NN of_IN
          constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD does_VBZ not_RB appear_VB to_TO be_VB
          mediated_JJ by_IN changes_NNS in_IN protein_NN degradation_NN ._.
        
        
          Expression_NNP of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD does_VBZ not_RB
          alter_VB p_NN 27_CD Kip_NNP 1_CD mRNA_NN levels_NNS but_CC decreases_NNS cyclin_NN D_NNP 1_CD mRNA_NN
          levels_NNS
          To_TO examine_VB whether_IN 4_CD EBP-_NNP 1_CD could_MD regulate_VB p_NN 27_CD Kip_NNP 1_CD or_CC
          cyclin_NN D_NNP 1_CD at_IN the_DT transcriptional_NN level_NN or_CC through_IN changes_NNS
          in_IN message_NN stability_NN ,_, the_DT levels_NNS of_IN p_NN 27_CD Kip_NNP 1_CD and_CC cyclin_NN D_NNP 1_CD
          mRNA_NN levels_NNS were_VBD examined_VBN by_IN Northern_NNP blotting_VBG (_( Fig_NNP ._.
          4_LS Aand_NNP 4_CD B_NNP )_) There_EX was_VBD no_DT difference_NN in_IN mRNA_NN levels_NNS encoding_VBG
          p_NN 27_CD Kip_NNP 1_CD after_IN treatment_NN with_IN pon_NN A_DT ._. However_RB ,_, pon_NN A_DT
          treatment_NN led_VBN to_TO an_DT approximately_RB 50_CD %_NN decrease_NN in_IN the_DT
          levels_NNS of_IN cyclin_NN D_NNP 1_CD mRNA_NN (_( Fig_NNP ._. 4_LS B_NNP )_) ._. This_DT may_MD contribute_VB
          to_TO the_DT downregulation_NN of_IN cyclin_NN D_NNP 1_CD protein_NN and_CC is_VBZ
          consistent_JJ with_IN a_DT previous_JJ report_NN showing_VBG an_DT increase_NN in_IN
          cyclin_NN D_NNP 1_CD mRNA_NN in_IN cells_NNS overexpressing_VBG eIF_NN 4_CD E_NNP [_NN 26_CD ]_NN ._.
        
        
          Expression_NNP of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT enhances_VBZ de_IN novop_NN 27_CD
          Kip_NNP 1_CD protein_NN synthesis_NN
          The_DT observation_NN that_DT expression_NN of_IN constitutively_RB
          active_JJ 4_CD EBP-_NNP 1_CD leads_VBZ to_TO increased_VB p_NN 27_CD Kip_NNP 1_CD ,_, but_CC does_VBZ not_RB
          significantly_RB affect_VB protein_NN turnover_NN or_CC mRNA_NN levels_NNS
          suggests_VBZ that_DT synthesis_NN of_IN p_NN 27_CD Kip_NNP 1_CD is_VBZ affected_VBN ._.
          Therefore_RB ,_, the_DT effect_NN of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT on_IN the_DT 
          de_IN novo_NN synthesis_NN of_IN p_NN 27_CD Kip_NNP 1_CD was_VBD
          tested_VBN by_IN metabolic_JJ labeling_VBG with_IN [_NN 35_CD S_NNP ]_NN -_: labeled_VBN amino_JJ
          acids_NNS ._. After_IN treatment_NN of_IN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS with_IN or_CC
          without_IN pon_NN A_DT for_IN 48_CD hours_NNS the_DT cells_NNS were_VBD pulse_NN labeled_VBN
          for_IN 1_CD ._. 5_CD hours_NNS ._. Half_NN of_IN the_DT cellular_JJ extract_NN was_VBD used_VBN to_TO
          immunoprecipitate_NN cyclin_NN D_NNP 1_CD and_CC the_DT other_JJ half_NN to_TO
          immunoprecipitate_NN p_NN 27_CD Kip_NNP 1_CD (_( Fig_NNP ._. 5_LS Aand_NNP 5_CD B_NNP )_) ._. The_DT results_NNS
          demonstrate_VBP an_DT increase_NN in_IN p_NN 27_CD Kip_NNP 1_CD protein_NN synthesis_NN of_IN
          approximately_RB two-fold_JJ in_IN cells_NNS expressing_VBG 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ._.
          Since_IN no_DT changes_NNS in_IN p_NN 27_CD Kip_NNP 1_CD mRNA_NN levels_NNS or_CC protein_NN
          turnover_NN were_VBD observed_VBN ,_, the_DT increased_VBN synthesis_NN of_IN p_NN 27_CD
          Kipmost_NNP likely_JJ reflects_VBZ increased_VBN rates_NNS of_IN translation_NN ._.
          In_IN the_DT same_JJ experiment_NN a_DT substantial_JJ decrease_NN in_IN 
          de_IN novo_NN synthesis_NN of_IN cyclin_NN D_NNP 1_CD was_VBD
          observed_VBN ,_, which_WDT could_MD be_VB due_JJ ,_, in_IN part_NN ,_, to_TO lower_JJR cyclin_NN D_NNP 1_CD
          mRNA_NN levels_NNS (_( see_VB Fig_NNP ._. 4_LS )_) ._. Interestingly_RB ,_, total_JJ protein_NN
          synthesis_NN ,_, as_IN determined_VBN by_IN trichloroacetic_JJ acid_NN (_( TCA_NNP )_)
          precipitation_NN of_IN total_JJ cellular_JJ proteins_NNS following_VBG pulse_NN
          labeling_VBG ,_, was_VBD decreased_VBN only_RB about_IN 15_CD %_NN by_IN expression_NN of_IN
          constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD (_( Fig_NNP ._. 5_LS B_NNP )_) ._. This_DT is_VBZ
          consistent_JJ with_IN reports_NNS that_IN changes_NNS in_IN the_DT levels_NNS of_IN
          active_JJ eIF_NN 4_CD E_NNP have_VBP a_DT much_RB greater_JJR effect_NN on_IN the_DT
          translation_NN of_IN specific_JJ classes_NNS of_IN mRNA_NN than_IN on_IN general_JJ
          translation_NN rates_NNS [_NN 15_CD 27_CD ]_NN ._.
        
        
          Expression_NNP of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT leads_VBZ to_TO inhibition_NN of_IN CDK_NNP 2_CD
          activity_NN
          A_DT critical_JJ factor_NN in_IN p_NN 27_CD Kip_NNP 1_CD -_: mediated_JJ cell_NN cycle_NN
          arrest_NN is_VBZ inhibition_NN of_IN CDK_NNP 2_CD ._. 4_LS EBP-_NNP 1_CD -_: 5_CD A_DT expression_NN did_VBD
          not_RB significantly_RB change_VB CDK_NNP 2_CD protein_NN levels_NNS (_( see_VB Fig_NNP ._.
          2_LS A_DT )_) ._. However_RB ,_, there_EX was_VBD a_DT substantial_JJ loss_NN of_IN CDK_NNP 2_CD
          activity_NN as_IN determined_VBN by_IN an_DT immunoprecipitation_NN kinase_NN
          assay_NN (_( Fig_NNP ._. 6_CD )_) ._. This_DT loss_NN of_IN CDK_NNP 2_CD activity_NN correlated_JJ
          with_IN an_DT increase_NN in_IN the_DT amount_NN of_IN p_NN 27_CD Kip_NNP 1_CD that_IN
          co-immunoprecipitated_JJ with_IN CDK_NNP 2_CD (_( Fig_NNP ._. 6_CD )_) ._. At_IN the_DT same_JJ
          time_NN ,_, the_DT association_NN of_IN p_NN 27_CD Kip_NNP 1_CD with_IN CDK_NNP 4_CD was_VBD
          dramatically_RB decreased_VBN (_( Fig_NNP ._. 6_CD )_) ._. These_DT results_NNS suggest_VBP
          that_IN 4_CD EBP-dependent_NNP cell_NN cycle_NN arrest_NN involves_VBZ p_NN 27_CD
          Kip_NNP 1_CD -_: mediated_JJ inhibition_NN of_IN CDK_NNP 2_CD kinase_NN activity_NN ._.
        
        
          Expression_NNP of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT
          enhances_VBZ cap-independent_JJ translation_NN through_IN the_DT p_NN 27_CD
          Kip_NNP 15_CD '_POS -_: UTR_NNP
          A_DT novel_NN finding_VBG of_IN the_DT experiments_NNS above_IN is_VBZ that_DT
          synthesis_NN of_IN endogenous_JJ p_NN 27_CD Kip_NNP 1_CD is_VBZ enhanced_VBN under_IN
          conditions_NNS that_WDT are_VBP expected_VBN to_TO reduce_VB cap-dependent_JJ
          translation_NN ._. One_CD possibility_NN is_VBZ that_IN the_DT p_NN 27_CD Kip_NNP 1_CD mRNA_NN is_VBZ
          translated_VBN through_IN a_DT cap-independent_JJ mechanism_NN that_WDT does_VBZ
          not_RB require_VB eIF_NN 4_CD E_NNP ._. It_PRP was_VBD recently_RB demonstrated_VBN that_IN
          elements_NNS within_IN a_DT 217_CD nucleotide_NN sequence_NN from_IN the_DT 5_CD '_POS -_: UTR_NNP
          of_IN the_DT mouse_NN p_NN 27_CD Kip_NNP 1_CD mRNA_NN is_VBZ able_JJ to_TO mediate_VB
          cap-independent_JJ translation_NN of_IN a_DT reporter_NN gene_NN in_IN NIH_NNP 3_CD T_NN 3_CD
          and_CC D_NNP 6_CD P_NN 2_CD T_NN cells_NNS [_NN 28_CD ]_NN ._. There_EX is_VBZ a_DT high_JJ level_NN of_IN
          sequence_NN homology_NN between_IN the_DT mouse_NN and_CC human_JJ 5_CD '_POS -_: UTRs_NNP and_CC
          the_DT major_JJ transcriptional_NN start_NN site_NN is_VBZ also_RB conserved_JJ [_NN
          29_CD ]_NN ._. Therefore_RB it_PRP is_VBZ likely_JJ the_DT 5_CD '_POS -_: UTR_NNP of_IN the_DT human_JJ p_NN 27_CD
          Kip_NNP 1_CD message_NN is_VBZ also_RB able_JJ to_TO mediate_VB cap-independent_JJ
          translation_NN initiation_NN ._. To_TO test_VB this_DT ,_, a_DT 472_CD nucleotide_NN
          fragment_NN ,_, representing_VBG the_DT full-length_JJ human_JJ p_NN 27_CD
          Kip_NNP 15_CD '_POS -_: UTR_NNP derived_VBD from_IN transcription_NN initiation_NN at_IN the_DT
          major_JJ start_NN site_NN ,_, was_VBD inserted_VBN into_IN the_DT bicistronic_JJ
          expression_NN vector_NN pGL_NN 2_CD CAT_NNP /_NN Luc_NNP [_NN 30_CD ]_NN ._. In_IN this_DT vector_NN ,_,
          the_DT first_JJ cistron_NN ,_, encoding_VBG chloramphenicol_NN
          acetyltransferase_NN (_( CAT_NNP )_) ,_, is_VBZ proximal_NN to_TO the_DT mRNA_NN 's_POS cap_NN
          structure_NN and_CC therefore_RB expected_VBN to_TO be_VB translated_VBN by_IN the_DT
          conventional_JJ cap-dependent_JJ translation_NN mode_NN ._. The_DT second_JJ
          cistron_NN ,_, encoding_VBG luciferase_NN ,_, is_VBZ downstream_JJ of_IN the_DT CAT_NNP
          stop_NN codon_NN and_CC therefore_RB must_MD be_VB translated_VBN by_IN a_DT
          cap-independent_JJ mechanism_NN mediated_JJ by_IN sequence_NN elements_NNS
          inserted_VBN between_IN the_DT two_CD cistrons_NNS ._. Bicistronic_NNP constructs_NNS
          without_IN an_DT insert_NN or_CC with_IN the_DT human_JJ p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP
          inserted_VBD in_IN either_DT the_DT correct_JJ or_CC reverse_VB orientation_NN
          were_VBD transiently_RB expressed_VBN in_IN MCF_NNP 7_CD cells_NNS ._. The_DT cells_NNS were_VBD
          harvested_VBN after_IN one_CD day_NN and_CC both_DT CAT_NNP and_CC luciferase_NN
          activities_NNS were_VBD analyzed_VBN (_( Fig_NNP ._. 7_CD Aand_NNP 7_CD B_NNP )_) ._. Expression_NNP of_IN
          CAT_NNP was_VBD nearly_RB identical_JJ with_IN all_DT three_CD constructs_NNS and_CC
          was_VBD therefore_RB independent_JJ of_IN an_DT insert_NN between_IN the_DT two_CD
          coding_VBG regions_NNS ._. In_IN contrast_NN ,_, only_RB the_DT construct_VB carrying_VBG
          the_DT p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP insert_VB in_IN the_DT correct_JJ orientation_NN
          expressed_VBD a_DT significant_JJ level_NN of_IN luciferase_NN ._. The_DT ratio_NN of_IN
          luciferase_NN /_NN CAT_NNP was_VBD enhanced_VBN approximately_RB 12_CD -_: fold_VB by_IN the_DT
          human_JJ 5_CD '_POS -_: UTR_NNP (_( Fig_NNP ._. 7_CD B_NNP )_) ._. Thus_RB the_DT full-length_JJ human_JJ p_NN 27_CD
          Kip_NNP 15_CD '_POS -_: UTR_NNP is_VBZ able_JJ to_TO mediate_VB cap-independent_JJ translation_NN
          in_IN a_DT manner_NN similar_JJ to_TO that_DT previously_RB shown_VBN for_IN the_DT 217_CD
          nucleotide_NN sequence_NN of_IN the_DT mouse_NN 5_CD '_POS -_: UTR_NNP [_NN 28_CD ]_NN ._.
          The_DT effect_NN of_IN constitutively_RB active_JJ 4_CD EBP-_NNP 1_CD on_IN the_DT
          activity_NN of_IN the_DT p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP was_VBD determined_VBN by_IN
          cotransfecting_VBG the_DT bicistronic_JJ construct_VB together_RB with_IN an_DT
          expression_NN vector_NN encoding_VBG 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT into_IN MCF_NNP 7_CD cells_NNS ._.
          Expression_NNP of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT led_VBN to_TO a_DT two-fold_JJ increase_NN in_IN the_DT
          luciferase_NN /_NN CAT_NNP ratio_NN (_( Fig_NNP ._. 7_CD C_NNP )_) ._. Interestingly_RB ,_, this_DT is_VBZ
          approximately_RB the_DT same_JJ level_NN of_IN increase_NN that_WDT is_VBZ observed_VBN
          in_IN synthesis_NN of_IN endogenous_JJ p_NN 27_CD Kip_NNP 1_CD protein_NN (_( see_VB Fig_NNP ._.
          5_LS B_NNP )_) ._.
        
      
      
        Discussion_NNP
        In_IN normal_JJ mitogen-activated_JJ cells_NNS eIF_NN 4_CD E_NNP activity_NN is_VBZ
        enhanced_VBN due_JJ to_TO elevated_VBD transcription_NN of_IN the_DT eIF_NN 4_CD E_NNP gene_NN ,_, a_DT
        phosphorylation-dependent_JJ increase_NN in_IN affinity_NN for_IN the_DT
        7_CD -_: methylguanosine_NN cap_NN ,_, and_CC phosphorylation-dependent_JJ
        inactivation_NN of_IN the_DT inhibitor_NN protein_NN 4_CD EBP_NNP ._. In_IN many_JJ tumor_NN
        cells_NNS eIF_NN 4_CD E_NNP levels_NNS are_VBP elevated_VBD and_CC overexpression_NN of_IN the_DT
        protein_NN in_IN normal_JJ cultured_JJ cells_NNS causes_NNS transformation_NN ._.
        Elevated_NNP eIF_NN 4_CD E_NNP levels_NNS enhance_VB translation_NN of_IN specific_JJ
        mRNAs_NNS ._. Many_JJ of_IN these_DT mRNAs_NNS are_VBP involved_VBN in_IN cell_NN cycle_NN
        progression_NN ._. They_PRP have_VBP long_JJ GC-rich_NNP 5_CD '_POS -_: UTRs_NNP that_WDT can_MD form_VB
        extensive_JJ secondary_JJ structure_NN and_CC have_VBP been_VBN classified_VBN as_IN
        "_'' weak_JJ "_'' mRNAs_NNS because_IN they_PRP are_VBP translated_VBN inefficiently_RB when_WRB
        eIF_NN 4_CD E_NNP levels_NNS are_VBP limiting_VBG (_( reviewed_VBN in_IN [_NN 15_CD ]_NN )_) ._. It_PRP has_VBZ
        been_VBN proposed_VBN that_IN when_WRB eIF_NN 4_CD E_NNP levels_NNS are_VBP elevated_VBD these_DT
        mRNAs_NNS can_MD more_RBR effectively_RB recruit_VB eIF_NN 4_CD E_NNP and_CC its_PRP$ associated_VBN
        factors_NNS including_VBG eIF_NN 4_CD G_NNP ,_, a_DT scaffold_NN protein_NN essential_JJ in_IN
        recruiting_VBG the_DT small_JJ ribosomal_JJ subunit_NN ,_, and_CC eIF_NN 4_CD A_DT ,_, a_DT
        helicase_NN essential_JJ for_IN scanning_VBG through_IN secondary_JJ
        structures_NNS in_IN the_DT 5_CD '_POS -_: UTR_NNP [_NN 15_CD 27_CD ]_NN ._.
        In_IN the_DT experiments_NNS described_VBD here_RB we_PRP have_VBP inducibly_RB
        expressed_VBN a_DT constitutively_RB active_JJ form_NN of_IN 4_CD EBP-_NNP 1_CD in_IN the_DT
        human_JJ breast_NN cancer_NN cell_NN line_NN MCF_NNP 7_CD ._. This_DT leads_VBZ to_TO nearly_RB
        complete_JJ inhibition_NN of_IN cell_NN proliferation_NN which_WDT is_VBZ
        associated_VBN with_IN an_DT increase_NN in_IN binding_JJ of_IN 4_CD EBP-_NNP 1_CD to_TO eIF_NN 4_CD E_NNP ._.
        This_DT does_VBZ not_RB lead_VB to_TO a_DT major_JJ drop_NN in_IN total_JJ protein_NN
        synthesis_NN as_IN indicated_VBN by_IN metabolic_JJ labeling_VBG with_IN 35_CD S-_NNP amino_JJ
        acids_NNS ._. However_RB ,_, there_EX are_VBP major_JJ changes_NNS in_IN expression_NN of_IN
        two_CD cell_NN cycle_NN regulatory_JJ proteins_NNS ,_, cyclin_NN D_NNP 1_CD and_CC p_NN 27_CD Kip_NNP 1_CD ._.
        Cyclin_NNP D_NNP 1_CD levels_NNS decline_VBP to_TO about_IN 30_CD %_NN of_IN that_DT observed_VBD in_IN
        uninduced_JJ cells_NNS and_CC this_DT appears_VBZ to_TO be_VB due_JJ to_TO a_DT reduction_NN
        in_IN cyclin_NN D_NNP 1_CD mRNA_NN levels_NNS and_CC protein_NN synthesis_NN ,_, since_IN there_EX
        was_VBD no_DT evidence_NN for_IN changes_NNS in_IN cyclin_NN D_NNP 1_CD turnover_NN ._. The_DT
        observed_VBN decline_NN in_IN cyclin_NN D_NNP 1_CD is_VBZ expected_VBN since_IN
        constitutively_RB active_JJ 4_CD EBP_NNP should_MD reverse_VB cyclin_NN D_NNP 1_CD
        expression_NN mediated_JJ by_IN eIF_NN 4_CD E_NNP overexpression_NN ._. Interestingly_RB ,_,
        others_NNS have_VBP demonstrated_VBN that_DT eIF_NN 4_CD E_NNP has_VBZ an_DT additional_JJ role_NN
        in_IN the_DT nucleus_NN ._. A_DT portion_NN of_IN the_DT cellular_JJ eIF_NN 4_CD E_NNP is_VBZ imported_VBN
        into_IN the_DT nucleus_NN through_IN a_DT mechanism_NN that_WDT requires_VBZ the_DT
        protein_NN 4_CD E-T_NNP [_NN 31_CD ]_NN ._. In_IN the_DT nucleus_NN eIF_NN 4_CD E_NNP is_VBZ localized_VBN to_TO
        specific_JJ nuclear_JJ bodies_NNS and_CC associates_NNS with_IN promyelocytic_JJ
        leukemia_NN protein_NN (_( PML_NNP ,_, [_NN 32_CD ]_NN )_) ._. Nuclear_NNP eIF_NN 4_CD E_NNP appears_VBZ to_TO
        be_VB involved_VBN in_IN export_NN of_IN cyclin_NN D_NNP 1_CD mRNA_NN to_TO the_DT cytosol_NN [_NN 25_CD
        ]_NN ._. Both_DT 4_CD E-T_NNP and_CC PML_NNP interact_NN with_IN the_DT same_JJ domain_NN of_IN
        eIF_NN 4_CD E_NNP that_IN binds_NNS 4_CD EBP_NNP [_NN 32_CD ]_NN ._. Thus_RB expression_NN of_IN
        constitutively_RB active_JJ 4_CD EBP_NNP may_MD block_VB nuclear_JJ functions_NNS of_IN
        eIF_NN 4_CD E_NNP ,_, one_CD consequence_NN being_VBG a_DT reduction_NN in_IN cyclin_NN D_NNP 1_CD mRNA_NN
        that_WDT can_MD be_VB translated_VBN in_IN the_DT cytoplasm_NN ._.
        In_IN contrast_NN to_TO cyclin_NN D_NNP 1_CD ,_, p_NN 27_CD Kip_NNP 1_CD levels_NNS increase_VBP when_WRB
        4_CD EBP-_NNP 1_CD -_: 5_CD A_DT is_VBZ expressed_VBN ._. An_DT interesting_JJ note_NN is_VBZ that_IN the_DT p_NN 27_CD
        Kip_NNP 1_CD mRNA_NN has_VBZ a_DT long_JJ 5_CD '_POS -_: UTR_NNP that_WDT is_VBZ 65_CD %_NN GC_NNP and_CC is_VBZ predicted_VBN
        to_TO form_VB stable_JJ secondary_JJ structures_NNS [_NN 29_CD ]_NN ._. Thus_RB ,_, even_RB
        though_IN it_PRP shares_VBZ these_DT characteristics_NNS with_IN the_DT putative_JJ
        "_'' weak_JJ "_'' mRNAs_NNS that_WDT require_VBP elevated_VBD eIF_NN 4_CD E_NNP activity_NN for_IN
        efficient_JJ translation_NN ,_, p_NN 27_CD Kip_NNP 1_CD responds_VBZ in_IN an_DT opposite_JJ
        manner_NN ._. Part_NN of_IN this_DT can_MD be_VB explained_VBN by_IN the_DT fact_NN that_IN the_DT
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP is_VBZ able_JJ to_TO promote_VB cap-independent_JJ
        translation_NN ._. When_WRB placed_VBN between_IN the_DT CAT_NNP and_CC luciferase_NN
        coding_VBG regions_NNS in_IN a_DT bicistronic_JJ mRNA_NN ,_, the_DT 5_CD '_POS -_: UTR_NNP stimulates_NNS
        high_JJ level_NN expression_NN of_IN the_DT downstream_JJ coding_VBG region_NN
        (_( luciferase_NN )_) ._. This_DT property_NN is_VBZ shared_VBN by_IN the_DT highly_RB
        homologous_RB mouse_NN p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP [_NN 28_CD ]_NN ._. Coexpression_NNP of_IN
        4_CD EBP-_NNP 1_CD -_: 5_CD A_DT with_IN the_DT bicistronic_JJ construct_VB containing_VBG the_DT p_NN 27_CD
        Kip_NNP 15_CD '_POS -_: UTR_NNP leads_VBZ to_TO an_DT approximately_RB two-fold_JJ increase_NN in_IN
        cap-independent_JJ expression_NN ._. This_DT increase_NN is_VBZ similar_JJ to_TO
        that_DT observed_VBD for_IN endogenous_JJ p_NN 27_CD Kip_NNP 1_CD in_IN cells_NNS induced_VBN to_TO
        express_VB 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ._. The_DT mechanism_NN by_IN which_WDT 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT could_MD
        mediate_VB enhanced_JJ translation_NN through_IN the_DT p_NN 27_CD Kip_NNP 15_CD '_POS -_: UTR_NNP is_VBZ
        not_RB presently_RB known_VBN ._. One_CD possibility_NN is_VBZ that_IN binding_JJ of_IN
        4_CD EBP-_NNP 1_CD to_TO eIF_NN 4_CD E_NNP releases_NNS other_JJ initiation_NN factors_NNS that_WDT are_VBP
        in_IN limited_JJ supply_NN but_CC also_RB required_VBN for_IN cap-independent_JJ
        initiation_NN ._.
        Inhibition_NNP of_IN cell_NN proliferation_NN by_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT correlates_NNS
        with_IN a_DT large_JJ decrease_NN in_IN CDK_NNP 2_CD activity_NN ._. This_DT is_VBZ not_RB due_JJ to_TO
        a_DT decline_NN in_IN CDK_NNP 2_CD or_CC cyclin_NN E_NNP protein_NN levels_NNS ._. Rather_RB it_PRP
        corresponds_NNS to_TO enhanced_VBN binding_JJ of_IN p_NN 27_CD Kip_NNP 1_CD to_TO the_DT cyclin_NN
        E_NNP /_NN CDK_NNP 2_CD complex_JJ ._. This_DT is_VBZ probably_RB mediated_JJ by_IN two_CD separate_JJ
        mechanisms_NNS ._. First_LS ,_, downregulation_NN of_IN cyclin_NN D_NNP 1_CD leads_VBZ to_TO
        release_NN of_IN p_NN 27_CD Kip_NNP 1_CD sequestered_VBN by_IN the_DT cyclin_NN D_NNP 1_CD /_NN CDK_NNP 4_CD
        complex_JJ ._. This_DT is_VBZ indicated_VBN by_IN a_DT large_JJ decrease_NN in_IN
        co-immunoprecipitation_JJ of_IN p_NN 27_CD Kip_NNP 1_CD with_IN CDK_NNP 4_CD upon_IN induction_NN
        of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ._. Second_JJ ,_, 
        de_IN novo_NN synthesis_NN contributes_VBZ to_TO the_DT
        pool_NN of_IN cellular_JJ p_NN 27_CD Kip_NNP 1_CD that_WDT is_VBZ available_JJ to_TO bind_NN the_DT
        cyclin_NN E_NNP /_NN CDK_NNP 2_CD complex_JJ ._.
        Given_VBN its_PRP$ role_NN in_IN control_NN of_IN cell_NN proliferation_NN and_CC in_IN
        tumorigenesis_NNS ,_, there_EX is_VBZ interest_NN in_IN targeting_VBG the_DT pathways_NNS
        that_WDT control_NN eIF_NN 4_CD E_NNP activity_NN for_IN cancer_NN chemotherapy_NN ._.
        Clinical_NNP trials_NNS using_VBG the_DT rapamycin_NN analog_NN CCI-_NNP 779_CD show_NN
        promise_NN for_IN this_DT strategy_NN [_NN 22_CD ]_NN ._. Rapamycin_NNP and_CC its_PRP$
        synthetic_JJ analogs_NNS block_VBP mTOR_NN kinase_NN activity_NN leading_VBG to_TO
        dephosphorylation_NN of_IN 4_CD EBP_NNP and_CC other_JJ mTOR_NN substrates_NNS ._. MCF_NNP 7_CD
        cells_NNS are_VBP sensitive_JJ to_TO rapamycin_NN analogs_NNS in_IN the_DT low_JJ nM_NN
        range_NN [_NN 33_CD ]_NN ._. A_DT potential_JJ problem_NN with_IN the_DT use_NN of_IN
        rapamycin_NN and_CC its_PRP$ analogs_NNS is_VBZ that_IN some_DT tumors_NNS are_VBP
        intrinsically_RB resistant_JJ to_TO its_PRP$ effects_NNS [_NN 33_CD 34_CD ]_NN ._.
        Resistance_NNP in_IN mammalian_JJ cells_NNS has_VBZ been_VBN associated_VBN with_IN
        decreased_VBD expression_NN of_IN 4_CD EBP-_NNP 1_CD [_NN 35_CD ]_NN ,_, mutations_NNS in_IN the_DT
        ATM_NNP protein_NN [_NN 36_CD ]_NN ,_, and_CC low_JJ level_NN expression_NN of_IN p_NN 27_CD
        Kip_NNP 1_CD due_JJ to_TO enhanced_JJ turnover_NN of_IN the_DT protein_NN [_NN 37_CD ]_NN ._. In_IN
        addition_NN ,_, it_PRP has_VBZ been_VBN demonstrated_VBN that_IN fibroblasts_NNS from_IN
        p_NN 27_CD Kip_NNP 1_CD knockout_NN mice_NNS are_VBP more_RBR resistant_JJ to_TO the_DT effects_NNS of_IN
        rapamycin_NN than_IN normal_JJ cells_NNS [_NN 37_CD ]_NN ._. Thus_RB p_NN 27_CD Kip_NNP 1_CD is_VBZ an_DT
        important_JJ mediator_NN of_IN cell_NN growth_NN inhibition_NN in_IN response_NN to_TO
        rapamycin_NN ._. Many_JJ tumor_NN cells_NNS express_VBP very_RB low_JJ levels_NNS of_IN p_NN 27_CD
        Kip_NNP 1_CD and_CC this_DT is_VBZ correlated_JJ with_IN poor_JJ prognosis_NN ._. If_IN
        rapamycin_NN and_CC its_PRP$ analogs_NNS are_VBP to_TO be_VB developed_VBN as_IN useful_JJ
        antitumor_NN agents_NNS ,_, it_PRP will_MD be_VB important_JJ to_TO determine_VB how_WRB p_NN 27_CD
        Kip_NNP 1_CD levels_NNS affect_VBP responsiveness_NNS to_TO these_DT compounds_NNS ._.
        Rapamycin_NNP and_CC its_PRP$ analogs_NNS affect_VBP all_DT of_IN the_DT downstream_JJ
        targets_NNS of_IN mTOR_NN ,_, including_VBG p_NN 70_CD S_NNP 6_CD kinase_NN and_CC other_JJ
        components_NNS of_IN the_DT translation_NN machinery_NN ._. The_DT data_NNS presented_VBN
        here_RB indicate_VBP that_IN direct_JJ inhibition_NN of_IN eIF_NN 4_CD E_NNP may_MD be_VB more_RBR
        effective_JJ and_CC a_DT more_RBR specific_JJ means_NNS of_IN targeting_VBG tumor_NN
        cells_NNS than_IN treatment_NN with_IN rapamycin_NN ._. It_PRP will_MD be_VB important_JJ
        to_TO determine_VB if_IN direct_JJ inhibition_NN of_IN eIF_NN 4_CD E_NNP is_VBZ able_JJ to_TO
        arrest_VB the_DT cell_NN cycle_NN in_IN rapamycin_NN resistant_JJ tumors_NNS ._. If_IN so_RB ,_,
        it_PRP may_MD be_VB possible_JJ to_TO develop_VB reagents_NNS that_WDT target_NN eIF_NN 4_CD E_NNP
        activity_NN ,_, thereby_RB bypassing_VBG the_DT upstream_RB signaling_VBG events_NNS
        in_IN the_DT pathway_NN ._.
      
      
        Methods_NNP
        
          Cell_NNP culture_NN
          MCF_NNP 7_CD cells_NNS were_VBD cultured_JJ in_IN Dulbecco_NNP 's_POS modified_VBN
          Eagle_NNP 's_POS medium_NN (_( DMEM_NNP )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN
          serum_NN (_( FCS_NNP )_) ,_, 100_CD U_NNP /_NN ml_NN penicillin_NN ,_, and_CC 100_CD μg_NN /_NN ml_NN
          streptomycin_NN ._. The_DT inducible_JJ MCF_NNP 7_CD cell_NN line_NN expressing_VBG
          4_CD EBP-_NNP 1_CD -_: 5_CD A_DT was_VBD established_VBN using_VBG the_DT Complete_JJ Control_NNP ™_NN
          Inducible_NNP Mammalian_NNP Expression_NNP System_NNP (_( Stratagene_NNP )_) ._.
          First_LS ,_, MCF_NNP 7_CD cells_NNS were_VBD transfected_JJ with_IN the_DT pERV_NN 3_CD vector_NN
          encoding_VBG both_DT the_DT RXR_NNP protein_NN and_CC an_DT
          ecdysone_NN /_NN glucocorticoid_NN receptor_NN fusion_NN protein_NN using_VBG
          GenePorter_NNP (_( Gene_NNP Therapy_NNP Systems_NNPS )_) ._. Stably_NNP transfected_JJ
          colonies_NNS were_VBD selected_VBN using_VBG G_NNP 418_CD (_( 400_CD μg_NN /_NN ml_NN )_) ._. These_DT
          colonies_NNS were_VBD further_RBR screened_VBD for_IN the_DT ability_NN to_TO
          inducibly_RB express_VB luciferase_NN from_IN the_DT pEGSH-luc_JJ construct_VB
          in_IN response_NN to_TO pon_NN A_DT in_IN transient_JJ transfection_NN assays_NNS ._. A_DT
          responsive_JJ cell_NN line_NN derived_VBN in_IN this_DT manner_NN (_( designated_VBN
          MCF_NNP 7_CD -_: pERV_NN 3_LS )_) was_VBD further_JJ transfected_JJ with_IN pEGSH-_NN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ,_,
          a_DT construct_VB in_IN which_WDT a_DT constitutively_RB active_JJ form_NN of_IN
          4_CD EBP-_NNP 1_CD is_VBZ inserted_VBN into_IN the_DT pon_NN A-_NNP inducible_JJ expression_NN
          cassette_NN of_IN pEGSH_NN ._. Cell_NNP clones_NNS were_VBD selected_VBN using_VBG
          hygromycin_NN B_NNP (_( 100_CD μg_NN /_NN ml_NN )_) ._. The_DT resulting_VBG colonies_NNS were_VBD
          isolated_VBN ,_, expanded_VBN ,_, and_CC tested_VBD for_IN pon_NN A-_NNP inducible_JJ
          expression_NN of_IN 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT ._. A_DT single_NN stably_RB transfected_JJ cell_NN
          line_NN designated_VBN MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT was_VBD used_VBN in_IN the_DT
          experiments_NNS described_VBD ._.
        
        
          Transfections_NNP and_CC reporter_NN assays_NNS
          Cells_NNP growing_VBG in_IN 35_CD mm_NN plates_NNS were_VBD transfected_JJ using_VBG
          GenePorter_NNP ._. One_CD day_NN after_IN transfection_NN cells_NNS were_VBD lysed_JJ
          using_VBG reporter_NN lysis_NNS buffer_NN (_( Promega_NNP )_) and_CC scraped_JJ from_IN
          the_DT dishes_NNS ._. Luciferase_NNP activity_NN was_VBD determined_VBN using_VBG the_DT
          Steady-_NNP Glo_NNP substrate_NN (_( Promega_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ,_, using_VBG 50_CD μl_NN of_IN cellular_JJ extract_NN ._.
          CAT_NNP enzyme_NN activity_NN was_VBD determined_VBN using_VBG 14_CD C-_NNP labeled_VBD
          chloramphenicol_NN as_IN described_VBN previously_RB [_NN 38_CD ]_NN ._.
        
        
          Plasmid_NNP constructs_NNS
          The_DT human_JJ p_NN 27_CD Kip_NNP 15_CD '_POS UTR_NNP was_VBD amplified_VBN by_IN PCR_NNP using_VBG
          primers_NNS CCCAAGCTTTCTCCCGGGTCTGCACGACCGCCTCT_NNP and_CC
          CCCAAGCTTCTTCGTCAGCCTCCCTTCCAC_NNP ._. The_DT PCR_NNP product_NN was_VBD
          digested_VBN with_IN Hind_NNP III_NNP and_CC ligated_JJ into_IN the_DT Hind_NNP III_NNP site_NN
          of_IN pGL_NN 2_CD CAT_NNP /_NN Luc_NNP (_( a_DT gift_NN of_IN R_NN ._. E_NNP ._. Rhoads_NNP )_) ._. To_TO subclone_NN
          4_CD EBP-_NNP 1_CD -_: 5_CD A_DT into_IN pEGSH_NN the_DT plasmid_NN pcDNA_NN 3_CD ._. 1_LS -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT was_VBD
          digested_VBN with_IN Hind_NNP III_NNP ,_, the_DT ends_NNS were_VBD filled_VBN using_VBG Klenow_NNP
          fragment_NN ,_, and_CC then_RB the_DT insert_NN was_VBD released_VBN by_IN digesting_VBG
          with_IN Xba_NNP I_PRP ._. The_DT resulting_VBG fragment_NN was_VBD ligated_JJ into_IN pEGSH_NN
          that_WDT had_VBD been_VBN digested_VBN with_IN Eco_NNP RV_NN and_CC Xba_NNP I_PRP ._.
        
        
          Cell_NNP proliferation_NN assay_NN
          MCF_NNP 7_CD and_CC MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS were_VBD treated_VBN with_IN pon_NN A_DT
          (_( 10_CD μM_NN )_) or_CC the_DT same_JJ volume_NN of_IN ethanol_NN for_IN 5_CD days_NNS ._. The_DT
          medium_NN was_VBD changed_VBN every_DT day_NN ._. After_IN 1_CD ,_, 3_CD ,_, or_CC 5_CD days_NNS
          incubation_NN ,_, cells_NNS were_VBD harvested_VBN using_VBG trypsin_NN and_CC the_DT
          cell_NN number_NN was_VBD determined_VBN using_VBG a_DT hemacytometer_NN ._.
        
        
          Western_NNP blotting_VBG
          Cells_NNP were_VBD harvested_VBN by_IN trypsinization_NN and_CC the_DT cell_NN
          number_NN was_VBD determined_VBN using_VBG a_DT hemacytometer_NN ._. The_DT cells_NNS
          were_VBD pelleted_JJ and_CC washed_VBN with_IN phosphate-buffered_JJ saline_NN
          (_( PBS_NNP )_) ._. The_DT cell_NN pellets_NNS were_VBD resuspended_JJ in_IN sodium_NN
          dodecylsulfate_NN (_( SDS_NNP )_) -_: sample_NN buffer_NN at_IN 1_CD ×_NN 10_CD 4_CD cells_NNS per_IN
          μl_NN and_CC then_RB sonicated_JJ to_TO shear_NN nucleic_JJ acids_NNS ._. Samples_NNP
          representing_VBG 2_CD ×_NN 10_CD 5_CD cells_NNS were_VBD separated_VBN by_IN
          SDS-polyacrylamide_NNP gel_NN electrophoresis_NNS (_( SDS-PAGE_NNP )_) and_CC
          transferred_VBN to_TO Immobilion_NNP P_NN membranes_NNS ._. Membranes_NNP were_VBD
          probed_JJ with_IN the_DT appropriate_JJ antibodies_NNS ._. The_DT p_NN 27_CD Kip_NNP 1_CD and_CC
          eIF_NN 4_CD E_NNP monoclonal_NN antibodies_NNS were_VBD purchased_VBN from_IN
          Transduction_NNP Laboratories_NNPS ._. Anti-_NNP PHAS_NNP 1_CD (_( 4_CD EBP-_NNP 1_LS )_) polyclonal_NN
          antibody_NN was_VBD purchased_VBN from_IN Zymed_NNP ._. Anti-β-actin_NNP
          monoclonal_NN antibody_NN was_VBD purchased_VBN from_IN Sigma_NNP ._. Antibodies_NNP
          against_IN cyclin_NN D_NNP 1_CD ,_, CDK_NNP 2_CD ,_, and_CC CDK_NNP 4_CD were_VBD purchased_VBN from_IN
          Santa_NNP Cruz_NNP Biotechnology_NNP ._. Secondary_JJ horseradish_NN
          peroxidase-linked_JJ anti-mouse_JJ or_CC anti-rabbit_JJ IgG_NNP
          antibodies_NNS were_VBD purchased_VBN from_IN Santa_NNP Cruz_NNP Biotechnology_NNP ._.
          Bands_NNP were_VBD visualized_JJ using_VBG the_DT SuperSignal_NNP West_NNP Pico_NNP
          chemiluminescence_NN detection_NN system_NN (_( Pierce_NNP )_) ._.
        
        
          Protein_NNP turnover_NN analysis_NN
          MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS were_VBD cultured_JJ in_IN the_DT presence_NN or_CC
          absence_NN of_IN pon_NN A_DT (_( 10_CD μM_NN )_) for_IN 24_CD hours_NNS ._. The_DT medium_NN was_VBD
          then_RB changed_JJ with_IN readdition_NN of_IN pon_NN A_DT or_CC an_DT equal_JJ volume_NN
          of_IN ethanol_NN and_CC the_DT protein_NN synthesis_NN inhibitor_NN
          cycloheximide_NN (_( 100_CD μg_NN /_NN ml_NN ,_, Sigma_NNP )_) was_VBD added_VBN ._. Cells_NNP were_VBD
          incubated_JJ for_IN the_DT indicated_VBN times_NNS and_CC then_RB harvested_VBN in_IN
          SDS-sample_NNP buffer_NN as_IN described_VBN above_IN for_IN Western_NNP
          blotting_VBG ._. Cyclin_NNP D_NNP 1_CD and_CC p_NN 27_CD Kip_NNP 1_CD proteins_NNS were_VBD detected_VBN by_IN
          Western_NNP blotting_VBG and_CC the_DT levels_NNS of_IN each_DT protein_NN were_VBD
          estimated_VBN by_IN densitometry_NN using_VBG a_DT ChemiImager_NNP system_NN
          (_( Alpha_NNP Innotech_NNP )_) ._.
        
        
          Cap-binding_NNP assay_NN
          MCF_NNP 7_CD -_: 4_CD EBP-_NNP 1_CD -_: 5_CD A_DT cells_NNS were_VBD cultured_JJ in_IN the_DT presence_NN or_CC
          absence_NN of_IN pon_NN A_DT (_( 10_CD mM_NN )_) for_IN 48_CD hours_NNS ._. Cell_NNP monolayers_NNS
          were_VBD washed_VBN with_IN PBS_NNP three_CD times_NNS and_CC then_RB lysed_JJ in_IN lysis_NNS
          buffer_NN (_( 50_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, 150_CD mM_NN KCl_NNP ,_, 1_CD mM_NN
          dithiothreitol_NN ,_, 1_CD mM_NN EDTA_NNP ,_, 10_CD μg_NN /_NN ml_NN leupeptin_NN ,_, 2_CD μg_NN /_NN ml_NN
          Aprotinin_NNP ,_, and_CC 0_CD ._. 1_CD mM_NN PMSF_NNP )_) by_IN subjecting_VBG the_DT cells_NNS to_TO 3_CD
          cycles_NNS of_IN freezing_NN in_IN liquid_JJ nitrogen_NN and_CC thawing_VBG in_IN a_DT
          37_CD °_NN C_NNP water_NN bath_NN ._. The_DT lysate_NN was_VBD then_RB centrifuged_JJ at_IN full_JJ
          speed_NN in_IN a_DT microcentrifuge_NN at_IN 4_CD °_NN C_NNP for_IN 15_CD min_NN ._. The_DT
          supernatants_NNS were_VBD incubated_JJ with_IN 50_CD μl_NN of_IN
          7_CD -_: methyl-_NN GTP-Sepharose_NNP (_( Amersham_NNP Pharmacia_NNP Biotech_NNP ,_, Inc_NNP ._. )_)
          at_IN 4_CD °_NN C_NNP for_IN 2_CD hours_NNS on_IN a_DT rotator_NN ._. The_DT resin_NN was_VBD washed_VBN
          three_CD times_NNS with_IN lysis_NNS buffer_NN and_CC resuspended_JJ in_IN 50_CD μl_NN of_IN
          SDS-sample_NNP buffer_NN ._. Proteins_NNPS were_VBD resolved_VBN by_IN SDS-PAGE_NNP and_CC
          transferred_VBN to_TO Immobilon_NNP P_NN membranes_NNS ._. eIF_NN 4_CD E_NNP and_CC 4_CD EBP-_NNP 1_CD
          were_VBD detected_VBN by_IN Western_NNP blotting_VBG ._.
        
        
          Immunoprecipitation_NNP ,_, pulse-labeling_JJ and_CC CDK_NNP 2_CD kinase_NN
          assays_NNS
          Cell_NNP extracts_NNS were_VBD prepared_VBN using_VBG a_DT lysis_NNS buffer_NN
          consisting_VBG of_IN 50_CD mM_NN HEPES_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, 150_CD mM_NN NaCl_NNP ,_, 1_CD mM_NN
          EDTA_NNP ,_, 2_CD ._. 5_CD mM_NN EGTA_NNP ,_, 10_CD %_NN glycerol_NN ,_, 0_CD ._. 1_CD %_NN Tween-_NNP 20_CD ,_, 1_CD mM_NN DTT_NNP ,_,
          1_CD mM_NN NaF_NNP ,_, 0_CD ._. 1_CD mM_NN Na_NNP 
          3_CD VO_NNP 
          4_CD ,_, 10_CD μg_NN /_NN ml_NN leupeptin_NN ,_, 2_CD μg_NN /_NN ml_NN
          Aprotinin_NNP ,_, and_CC 0_CD ._. 1_CD mM_NN PMSF_NNP ._. Extracts_NNP were_VBD briefly_NN
          sonicated_JJ and_CC then_RB centrifuged_JJ at_IN full_JJ speed_NN in_IN a_DT
          microcentrifuge_NN at_IN 4_CD °_NN C_NNP for_IN 15_CD min_NN ._. Protein_NNP concentration_NN
          was_VBD determined_VBN using_VBG the_DT Bio-_NNP Rad_NNP protein_NN assay_NN
          solution_NN ._.
          For_IN pulse-labeling_JJ ,_, the_DT cells_NNS were_VBD washed_VBN three_CD times_NNS
          with_IN DMEM_NNP lacking_VBG Met_NNP and_CC Cys_NNP and_CC then_RB incubated_JJ in_IN the_DT
          same_JJ medium_NN containing_VBG 80_CD μCi_NN /_NN ml_NN of_IN 35_CD S-_NNP labeled_VBD Met_NNP and_CC
          Cys_NNP (_( Tran_NNP 35_CD S-_NNP label_NN ,_, ICN_NNP )_) and_CC the_DT proteasome_NN inhibitor_NN
          MG-_NNP 132_CD (_( 10_CD μM_NN ,_, Calbiochem_NNP )_) for_IN 1_CD ._. 5_CD hours_NNS ._. The_DT cells_NNS were_VBD
          washed_VBN three_CD times_NNS with_IN ice-cold_JJ PBS_NNP and_CC lysed_JJ as_IN above_IN ._.
          A_DT portion_NN of_IN the_DT supernatant_NN was_VBD precipitated_VBD with_IN TCA_NNP to_TO
          estimate_VB the_DT level_NN of_IN total_JJ protein_NN synthesis_NN ._. The_DT
          remainder_NN of_IN the_DT cell_NN extract_NN was_VBD used_VBN for_IN
          immunoprecipitation_NN ._. Equal_NNP amounts_NNS of_IN total_JJ protein_NN from_IN
          each_DT extract_NN (_( 0_CD ._. 5_LS to_TO 1_CD mg_NN )_) were_VBD used_VBN for_IN analysis_NN ._. Cell_NNP
          lysates_NNS were_VBD incubated_JJ with_IN 2_CD μg_NN of_IN rabbit_NN polyclonal_NN
          antibody_NN overnight_JJ at_IN 4_CD °_NN C_NNP on_IN a_DT rotator_NN ._. Protein_NNP
          A-_NNP conjugated_JJ agarose_NN beads_NNS (_( 30_CD μl_NN )_) were_VBD added_VBN ,_, and_CC the_DT
          incubation_NN continued_VBD for_IN 1_CD hour_NN on_IN a_DT rotator_NN ._. The_DT beads_NNS
          were_VBD pelleted_JJ and_CC washed_VBN five_CD times_NNS with_IN lysis_NNS buffer_NN ._.
          Next_JJ ,_, 30_CD μl_NN of_IN 2_CD X_NNP SDS-sample_NNP buffer_NN was_VBD added_VBN to_TO elute_NN
          immunoprecipitated_JJ proteins_NNS ._. Labeled_NNP proteins_NNS were_VBD
          resolved_VBN by_IN SDS-PAGE_NNP and_CC detected_VBN by_IN autoradiography_NN ._.
          For_IN CDK_NNP 2_CD kinase_NN assays_NNS ,_, lysates_NNS (_( 100_CD μg_NN protein_NN )_)
          prepared_VBN as_IN described_VBN above_IN were_VBD used_VBN to_TO
          immunoprecipitate_NN CDK_NNP 2_CD with_IN a_DT polyclonal_NN antibody_NN ._. The_DT
          beads_NNS with_IN the_DT bound_VBN proteins_NNS were_VBD washed_VBN and_CC then_RB
          resuspended_JJ in_IN 30_CD μl_NN of_IN kinase_NN buffer_NN [_NN 50_CD mM_NN HEPES_NNP ,_, pH_NN
          7_CD ._. 4_CD ,_, 2_CD ._. 5_CD mM_NN EGTA_NNP ,_, 10_CD mM_NN β-glycerophosphate_JJ ,_, 0_CD ._. 1_CD mM_NN
          vanadate_NN ,_, 1_CD mM_NN NaF_NNP ,_, 1_CD mM_NN DTT_NNP ,_, 10_CD mM_NN MgCl_NNP 
          2_CD ,_, 20_CD μM_NN ATP_NNP ,_, 50_CD μCi_NN γ-_NN 32_CD P-ATP_NNP (_( 7000_CD
          Ci_NNP /_NN mmol_NN ,_, ICN_NNP )_) ,_, and_CC 1_CD μg_NN histone_NN H_NNP 1_CD ]_NN ._. Reaction_NNP mixtures_NNS
          were_VBD incubated_JJ for_IN 15_CD min_NN at_IN 30_CD °_NN C_NNP and_CC stopped_VBN by_IN adding_VBG
          the_DT same_JJ volume_NN of_IN 2_CD X_NNP SDS-sample_NNP buffer_NN ._. The_DT
          phosphorylated_JJ histone_NN H_NNP 1_CD was_VBD resolved_VBN by_IN SDS-PAGE_NNP and_CC
          detected_VBN by_IN autoradiography_NN using_VBG Kodak_NNP XAR-_NNP 5_CD film_NN ._.
          For_IN co-immunoprecipitation_JJ of_IN p_NN 27_CD Kip_NNP 1_CD with_IN CDK_NNP 4_CD or_CC
          CDK_NNP 2_CD ,_, immunoprecipitations_NNS were_VBD performed_VBN as_IN described_VBN
          above_IN with_IN either_DT anti-_NN CDK_NNP 4_CD or_CC anti-_NN CDK_NNP 2_CD ._. The_DT
          precipitated_VBD proteins_NNS were_VBD dissolved_VBN in_IN SDS-sample_NNP
          buffer_NN ,_, separated_VBN by_IN SDS-PAGE_NNP and_CC then_RB p_NN 27_CD Kip_NNP 1_CD and_CC CDK_NNP 2_CD
          were_VBD detected_VBN by_IN Western_NNP blotting_VBG ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        HJ_NNP participated_VBD in_IN manuscript_NN preparation_NN and_CC design_NN and_CC
        performance_NN of_IN the_DT experiments_NNS ._. JC_NNP constructed_VBN and_CC
        characterized_VBD the_DT bicistronic_JJ reporter_NN constructs_NNS and_CC aided_VBN
        with_IN manuscript_NN preparation_NN ._. RM_NNP and_CC WKM_NNP conceived_VBD of_IN the_DT
        project_NN ,_, directed_VBD the_DT performance_NN of_IN the_DT experiments_NNS ,_, and_CC
        prepared_VBD the_DT final_JJ manuscript_NN ._. All_DT authors_NNS read_VBP and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
